Milk Oral Immunotherapy in Children to Treat Food Allergy

Primary Study Interventions

Prior to and after the desensitization, we will conduct double-blind placebo controlled food challenges to cow's milk protein. During the desensitization phase, we will give increasing doses of cow's milk protein by mouth on a weekly basis, as tolerated. The desensitization protocol starts with dilutional doses of milk and build up to a goal of 8 ounces of cow's milk.

Main Study Outcome Measure

The percentage of children completing the desensitization protocol in each study group will be the primary outcome measure.

Inclusion criteria

• Subjects must be age six to 17 years and have a history of cow's milk allergy. Subjects shall maintain strict avoidance of consumption of all cow's milk protein containing foods.
• Subjects will have a history (within the past six months) of a positive skin prick test to milk extract or an immunocap IgE level greater than 0.35 kilounits per liter (kU/L), and a positive allergic reaction history to milk within the past 12 months.
• Subjects must be in good health, as determined by medical history and physical examination performed by a study physician.
• Females of childbearing potential must be using an effective method of contraception, including abstinence, and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.
• Informed consent of parent or legal guardian is required.

Exclusion criteria

• Ability to tolerate eight ounces of cow's milk or eight grams of milk protein powder
• Pregnancy
• A history of soy allergy
• A history of food protein induced enterocolitis syndrome to milk
• A history of anaphylaxis requiring hospitalization
• A history of intubation related to asthma and/or a history of an intensive care unit admission for asthma management
• A current diagnosis of severe persistent asthma [forced expiratory volume in 1 second (FEV1) < 60% of predicted, as defined by National Heart, Lung, and Blood Institute (NHLBI) guidelines, despite current therapy
• A current diagnosis of severe atopic dermatitis
• A serious chronic medical condition, including neurologic, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease
• Use of oral or injection steroids within one month of protocol initial visit
• An acute illness within one week prior to the first dose of oral immunotherapy
• Use of antihistamines within seven days prior to double blind placebo controlled food challenge (DBPCFC)
• Use of chronic immunomodulatory therapy
• Participation in another experimental therapy study
• Participation in a study for the treatment of food allergy in the past 12 months
• Inability to discontinue antihistamines for skin testing and food challenges